Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Bvf Partners L. P/Il bought 1,505,932 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was bought at an average price of $9.84 per share, for a total transaction of $14,818,370.88. Following the purchase, the director now directly owns 4,688,954 shares of the company’s stock, valued at $46,139,307.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Olema Pharmaceuticals Trading Up 0.7 %
Shares of NASDAQ OLMA opened at $12.15 on Friday. The business’s 50 day moving average price is $9.75 and its 200 day moving average price is $7.00. Olema Pharmaceuticals, Inc. has a 52 week low of $2.19 and a 52 week high of $13.33.
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last issued its earnings results on Tuesday, August 8th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.24. On average, sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Institutional Investors Weigh In On Olema Pharmaceuticals
A number of large investors have recently bought and sold shares of the company. New York Life Investment Management LLC lifted its holdings in Olema Pharmaceuticals by 12.7% in the fourth quarter. New York Life Investment Management LLC now owns 133,157 shares of the company’s stock valued at $326,000 after acquiring an additional 15,008 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Olema Pharmaceuticals by 197.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 29,150 shares of the company’s stock valued at $101,000 after buying an additional 19,358 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Olema Pharmaceuticals by 122.5% during the 4th quarter. GSA Capital Partners LLP now owns 231,633 shares of the company’s stock valued at $568,000 after buying an additional 127,549 shares in the last quarter. Sectoral Asset Management Inc. lifted its holdings in Olema Pharmaceuticals by 63.3% in the 4th quarter. Sectoral Asset Management Inc. now owns 1,441,805 shares of the company’s stock valued at $3,532,000 after purchasing an additional 558,749 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Olema Pharmaceuticals in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 88.00% of the company’s stock.
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
- Five stocks we like better than Olema Pharmaceuticals
- ETF Screener: Uses and Step-by-Step Guide
- 2 Wrecked Stocks Keeping Cars on the Road Ready for Repair
- What Are Trending Stocks? Trending Stocks Explained
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- Earnings Per Share Calculator: How to Calculate EPS
- Shutterstock is the Value Stock they don’t want you to know about
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.